Please login to the form below

Not currently logged in

small cell lung cancer

This page shows the latest small cell lung cancer news and features for those working in and with pharma, biotech and healthcare.

EC approves Roche’s Tecentriq for early-stage lung cancer

EC approves Roche’s Tecentriq for early-stage lung cancer

Roche’s Tecentriq (atezolizumab) has been approved by the European Commission (EC) for adults with non-small cell lung cancer (NSCLC) who have a high risk of the disease reoccurring. ... Tecentriq was the first approved cancer immunotherapy for the

Latest news

More from news
Approximately 17 fully matching, plus 688 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 28 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

  • The heavy toll of COVID-19 on cancer patients

    During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. ... The therapy works predominantly on non-small cell lung cancer. The NHS has also rolled out four chemo-buses which allowed patients to take part in therapy

  • Delphi Technique Virtual Co-creation: A Customer Story

    The client’s main objectives were to:. Determine the current barriers to biomarker testing and biomarker-based treatment for non-small cell lung cancer (NSCLC), including differences in regional access and

  • Therapy Watch expands oncology and IBD portfolios

    Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer ... PCa), Renal Cell Carcinoma (RCC) and

  • Therapy Watch expands its oncology portfolio

    This month  Therapy Watch Oncology will be expanding its portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN). ... Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL),

  • How pembrolizumab will change the management of advanced lung cancer

    The results of the Phase III KEYNOTE-024 trial of pembrolizumab for non-small cell lung cancer (NSCLC) were presented by VJOncology Editorial Board Member Dr Martin Reck of LungenClinic Grosshansdorf. ... He explains that “this data will completely

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
Report: Omnichannel advice for the life science industry
In the latest issue of Delta magazine, Fishawack Health's Medical, Marketing, and Consulting experts share their practical advice for creating meaningful omnichannel stakeholder experiences and reveal our proprietary tool for...